Investor Event

Investor Event November 16, 2021

Forward Looking Statement and Non-GAAP Financial Information 2 This presentation contains statements

about the Company's future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those

indicated as a result of various important factors, including those discussed in the Company's most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available on the SEC's website, on the

Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any

subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.This presentation includes certain non-generally accepted

accounting principles (GAAP) financial measures that we use to describe our company's performance. The non-GAAP information presented provides investors with additional useful information but should not be considered in isolation or as

substitutes for the related GAAP measures. Moreover, other companies may define non-GAAP measures differently, which limits the usefulness of these measures for comparisons with such other companies. We encourage investors to review our

financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. An explanation of these non-GAAP financial measures and a reconciliation to the most directly comparable GAAP financial measure

are available on our website at bms.com/investors. Also note that a reconciliation of certain forward-looking statements, however, is not provided due to no reasonably accessible or reliable comparable GAAP measures for such statements and the

inherent difficulty in forecasting and quantifying such statements that are necessary for such reconciliation.

Today's Agenda 3 Rupert Vessey Samit Hirawat Chris Boerner David Elkins Giovanni

Caforio Strategic Overview Innovation Engine & Early Pipeline Late-Stage Pipeline Update Commercial Opportunities Financial Overview BREAK (10 min) Giovanni Caforio Closing, Q&A Conclusion, lunch reception 12:00 pm

Giovanni CaforioBoard Chair and Chief Executive Officer Strategic Overview

A differentiated biopharma company focused on innovative medicines for patients with cancer and other

serious diseases BEST OF BIOTECHBEST OF PHARMA Leading scientific innovationCollaborating at center of the biotech ecosystemLeveraging global scale and agilityDriven by the best people 5 Our strategic foundation

Diabetes business divested, e.g. Creating our biopharma company Focusing on specialty

medicines Deepening our innovation engine& long-term growth drivers BioPharma Strategyintroduced 2013 2007 2008 2009 2019 2020 2021 2017 2012 2010 2011 2014 2015 2016 2018 Continued

execution of biopharma strategy 6 New product portfolio launches LOE LOE LOE LOE acquisition divestiture Portfolio transformation enabled by strong track record of commercial execution

From 11 to 22 Phase 3 & registrational expansion opportunities Deepening our innovation engine since

2019 7 Deeper pipeline Expanded research platforms Industry leading Protein Homeostasis capability Expanding Cell Therapy platforms Broader external partnership network Currently >300 From 29 to 64 Phase 1 & 2 assets

Well positioned with a diverse portfolio of leading medicines 8 Leading Products across Four

Therapeutic Areas Robust Early-stage Pipeline** Across leading drug discovery platforms:Small moleculesProtein homeostasisBiologicsCell therapy **Phase I / II Assets Financial strength enabling continued investment for growth Solid Tumor

Oncology deucravacitinib* mavacamten* + Expansion opportunities across multiple assets 50+ assets Hematology Cardiovascular Immunology Deep & Broad Late-stage Pipeline New Product Portfolio rela+nivo FDC* milvexian BCMA

TCE cendakimab bempeg iberdomide FRa ADC CC-92480 * Anticipated launches

Our Commitment as a sustainable organization Embracing environmental stewardship 9 Experienced

& diverse Board Board oversight of strategy& key enterprise risks60% female & ethnically diverse directorsShareholder rightsRegular shareholder engagementProxy access Special meeting right (15%) Environment Governance Social Key

Priorities Concrete Commitments 2021 25% new clinical trial sites in diverse metro areas 2022 Gender parity at executive level2X representation for Black/African American & Hispanic/Latino executives 2025 $1B spend with diverse

suppliers 2024 Science-based emissions reduction targets established 2030 100% renewable electricity 2040 Net neutral GHG100% EV fleet100% equitable water useZero waste to landfill Maintaining highest ethics, integrity &

complianceUpholding Board oversight & accountability Promoting product quality & safetyCultivating diversity, equity & inclusionEnsuring health equity, patient access & innovation

Confidence in our ability to address future key LOE exposures 10 Mid to late stage

Pipeline Early-Stage Pipeline Financial strength New Product Portfolio 1H Decade Multiple drivers of growth to more than offset LOE headwinds 2H Decade $25B+ NRA revenue potential 50+ assets $45 - $50B free cash flow

2021-2023 milvexian BCMA TCE cendakimab bempeg iberdomide FRa ADC CC-92480 NRA: Non-Risk Adjusted sales subject to positive registrational trials and health authority approvalFinancial projections may contain non promoted sales, BMS

promotes only according to label

($12B - $14B) +$8B - $10B +$10B - $13B 2020 Revenues LOE Brands In-Line Brands Primarily I-O

& Eliquis 2025 Revenues New Product Portfolio Growth 2020-2025Low to mid-single digit revenue CAGR* 2020-2025 revenue growth:Continuing Business offsets LOEs 11 LOE Brands = Revlimid, Pomalyst, Sprycel, and Abraxane Not for Product

Promotional Use Continuing Business Financial projections may contain non promoted sales, BMS promotes only according to label *At constant exchange rates - Non-GAAP, on a risk-adjusted basis - There is no reliable or reasonable

estimable comparable GAAP metric for this non-GAAP forward-looking information

Revlimid, Eliquis & I-O Opportunity for a more diversified portfolio in 2025 12 Not for Product

Promotional Use New Product Portfolio All Other Eliquis & I-O New Product Portfolioexpected to represent ~25% of total company revenue expected in 2025, with continued growth expectedReduced concentration of top brands from ~70% in

2020 to ~50% in 2025; trend expected to continue Total Company Revenue Composition New Product Portfolio = Abecma, Breyanzi, Inrebic, Onureg, Reblozyl, Zeposia, deucravacitinib, mavacamten, rela + nivo FDC

New Product Portfolio has significant growth potential deucravacitinib $3B+ $4B+ Note: Non-risk

adjusted sales subject to positive registrational trials and health authority approval $1B+ mavacamten rela+nivo FDC Broad New Product Portfolio with $25B+non-risk adjusted revenue potential in 2029 13

Solid Tumor Onc $80B+ Lung $25B+ CRC $7B+ Breast $21B+ Prostate $10B+ Ovarian $2B+ Renal

$7B+ Melanoma $7B+ GI $1B+ H&N $2B+ Liver $1B+ Immunology $75B+ RA $28B+ Psoriasis $20B+ PsA $4B+ Ank. Spond. $1B+ Lupus $1B+ Atopic Derm $4B+ UC $6B+ Crohn's $13B+ Hematology $40B+ MM $20B+ NHL $11B+ MDS $1B+ AML

$1B+ CLL $6B+ Broad pipeline addresses diseases with significant commercial potential Mid to late-stage pipeline Early-stage pipeline milvexian BCMA TCE cendakimab bempeg iberdomide FRa ADC CC-92480 50+ assets Focused in

disease areas with large and growing commercial potential Cardiovascular $20B+ HF $3B+ Thrombosis $19B+ Source: EvaluatePharma 2020 estimates 14

Current focus: Emerging science-based in-licensing opportunitiesSmall & mid-sized bolt-on

opportunities to strengthen innovation engine & long-term growth profile Consistent criteria for sourcing external innovation Business Development remains a top priority 15 Strategically AlignedScientifically SoundFinancially

Attractive Not for Product Promotional Use OncologyHematologyImmunology Focusedon therapeutic areas of interest CardiovascularNeurology

New Product Portfolio and pipeline provide multiple pathways to growth from 2025 to 2029 New product

portfolio and pipeline products will continue to provide revenue replacement power, offsetting Eliquis and I-O LOEs Additional optionality from disciplined Business Development Delivery of late-stage pipelineCombination of new products

& high-value expansion opportunities:Reblozyl LCMdeucravacitinib LCMmavacamten LCMrelatlimab LCMmilvexianiberdomide 2025 Revenues LOE Brands 2029 Revenues Additional growth from New Product Portfolio Advancing robust

pipeline Diverse, growing New Product Portfolio Growth 2025-2029 16

Critical 2022 & 2023 deliverables to unlock value of New Product Portfolio Enable expansion

forReblozyl through successful1L MDS COMMANDS trial 17 deucravacitinib mavacamten Deliver successful launch of mavacamten over the next year Establish deucravacitinib as oralof choice in Psoriasis Establish broad access for Zeposia in

UC Build industry-leading cell therapy franchise, anchored on Breyanzi

What we will cover with you today 18 Provide insight to our innovation engine Rupert Vessey Samit

Hirawat Chris Boerner David Elkins Review ourmid & late-stage pipeline Discuss the building blocks of growth Review our financial strength & approach to capital allocation

Innovation Engine & Early Pipeline Rupert Vessey,MA, BM, BCh, FRCP, DPhil President, Research &

R&D Strategic Foundation An innovation company developing first-in-class & best-in-class

medicines addressing significant unmet need 20 External Partnerships Portfolio Execution Talent Key Enablers of Our Success Innovative R&D Platforms Digital Innovation

An Integrated Approach to Research and Development 21 Global Drug DevelopmentMaximize innovation

and productivity for late stage and LCM opportunities Research & Early DevelopmentDrive innovation and bring forward next generation assets

Differentiated and Diversified Portfolio Grown through Internal R&D and BD 22 Distribution

of clinical pipeline (2019 to 2021) # of assets Diversifying portfolio across TAs Rich early and mid-stage pipeline Modality agnostic

approach 5 2019 40 2021 4 3 86 Neuroscience Cardiovascular Hematology Fibrosis Immunology Oncology 86 11 2021 2019 Ph1, Ph2 Ph3, LCM 86 40 2021 2019 Biologic Small Molecule Cell Therapy 4 40

Industry Leading Drug Discovery Platforms 23 Complex Biotherapeutics Small Molecule Drug

Discovery Protein Homeostasis Cell Therapy Screening2.5MM Cmpds50K CelMods Hit ValidationExploratory SAR CryoEM Lead OptimizationMedchem - RadiochemML - Cheminformatics New Targets Drug Candidates Cro Network CAR T

technology: recognizes proteinson the surface of cancer cells TCR technology: recognizes intracellular tumor-specific proteins CAR TCR Probodies Immune Cell Engagers Bi-Specifics Site Specifics ADCs

Novel Assets Advancing from our Protein Homeostasis

Platform 24 CELMoD LDD Novel Target Cereblon Target Ligase Target ? Molecular Glue Heterobifunctional Intrinsic Degrader 1 2 3 Modalities Asset Indication Phase iberdomideA/I* CELMoD MM Late

Development CC-92480A/I* CELMoD MM Late Development CC-90009GSPT1 CELMoD AML Early Development CC-99282A/I* CELMoD Lymphoma Early Development CK1 CELMoD AML Early Development AR-LDD Prostate Cancer Early Development 2 Novel

LDD5 Novel CELMoD Heme-Onc, Inflammation Full Discovery * Aiolos/Ikaros

Broad Investment in Next Generation Cell Therapies 25 Engineered TCR T Cells for Solid Tumors CAR T

Armed Payload Recognizes intracellular targets Overcoming tumor microenvironment resistance Healthy donors Patients Allogeneic CAR T Cells Off the shelf alternative Enabled through strategic partnering Dual Antigen Targeting CAR

Ts Mitigating antigen loss

Immune Cell Engager Molecules are Complementary Modalities to Cellular Therapy 26 Current Portfolio

(public) Bispecific Antibodies: Direct host immune cells (T or NK) to recognize & attack tumor cells Indication Asset Disc Pre-clinical Ph1 AML CD33 NKE AML target NKE AML target NKE Lymphoma / CLL BCM

target NKE BCMA TCE Myeloma BCMA NKE BCMA TCE Solid Tumor Solid tumor target TCE ST target NKE ST target NKE Inflammation/neuroscience NS target

>85Active Collaborations 4INDs Filed 2021 9Licenses Optioned 2021 Internal R&ED Strengths are

Amplified through Active External Partnerships 27 Neuroscience Immuno- Oncology & Cell Therapy Oncogenesis Tumor Micro- Environment Mechanisms of Cancer Resistance Cross-Therapeutic Informatics & Predictive

Sciences Discovery Biothera-peutics Small Molecule Drug Discovery Inflammation, CV & Fibrosis EXEMPLAR MMPACT

Rapidly Advancing Neuroscience Pipeline Built through External Partner Network 28 By end of 2023, five

assets will have completed Phase 1 and two assets will have Phase 1 ongoing Machine learning Protein Homeostasis Protein Clearance RNA Splicing Remyelination and Repair Neuroinflammation Zeposia approved US and EU

2020 Mitophagy Endocannabinoid enhancer IND 2020: FIH June 2020 CC-97489 Multiple SclerosisNeuroinflammation

Opportunities for Visibility and Guidance Increasing Optionality for Additional Platforms and

Technologies via Strategic Equity Investments Potential 1st mover advantage for early data access and partnership opportunitiesBoard observer seats provide opportunities to provide guidance on research and development 29 Equity Portfolio

Focus Direct Equity LP Venture Capital Actively Managed Incubators Description Direct relationships with innovative companies seen as too early stage or inaccessible for broader partnership~ 75 investments Deliberately constructed

VC portfolio to provide access to innovation across geographies, company stages, TAs and sectors Partnerships between incubators and BMS support innovation arising from academic centers across multiple geographies Examples Pure direct

equity: Orna, AktisEquity structured with partnership: Arsenal Bio Company creation: Avalon BioventuresDedicated focus: Droia Genetic Medicines Fund Geographic diversity: LAB2030Incubator to Accelerator: Dark Blue Therapeutics ~$5B total

Integrating AI & Machine Learning into Drug Discovery and Development to Enable Better Decisions and

Faster Execution 30 Compound OptimizationReduced cycle times |Computer assisted design Phenotypic ScreeningNovel targets | CELMoD MoA Biomarker DiscoveryMulti-omics analysis | Digital pathology | Imaging Protocol Design

Competitive positioning | Virtual trial augmentation | Novel endpoints Hypothesis ValidationLarge internal datasets | Signal detection| Patient selection Trial ExecutionPatient data collection| Improved Site/Investigator

Communication CTDI Discovery through Proof-of-concept Registrational Program Execution

BCMA TCE GSPT1 CELMoD(CC-90009) Phase 1 POC / initiation of registrational development

Hematology Fibrosis Immunology Oncology Cardiovascular Neuroscience Phase 1 / Phase 2 Pipeline Anti-SIRP 1(CC-95251) BCMA CAR T(bb21217) BET Inhibitor1(CC-90010) BET Inhibitor (CC-95775) FXIa Inhibitor S1PR1 Modulator TYK2

Inhibitor Anti-TIGIT Anti-TIM3 CD3xPSCA2(GEM3PSCA) STING Agonist Anti-Fucosyl GM1 Anti-NKG2A3 motolimod BCMA ADC milvexian(FXIa Inhibitor) Opportunity for >20 POC decisions in the next three years CD19 NEX T3 BCMA NEX

T3 Anti-CTLA-4 NF PB Anti-OX40 FAAH/MGLLDual Inhibitor AR LDD3 FPR-2 Agonist CD47xCD203 GPRC5D CAR T3 CD33 NKE3 Anti-CD403 IL2-CD253 LSD1 Inhibitor1 TGF Inhibitor MK2 Inhibitor HSP47 branebrutinib Imm. Tolerance (Anokion)2 A/I

CELMoD (BCM)(CC-99282) Anti-CTLA-4 NF BET Inhibitor(BMS-986158) Anti-IL-8(BMS-986253) Anti-CTLA-4 PB LPA1 Antagonist FA-Relaxin afimetoran(TLR7/8 Inhibitor) danicamtiv Cardiac Myosin Inh.(MYK-224) Phase